Seung-Hyuk Shim1, Shin-Wha Lee1, Jeong-Yeol Park1, Young Seok Kim2, Dae-Yeon Kim1, Jong-Hyeok Kim1, Yong-Man Kim1, Young-Tak Kim1, Joo-Hyun Nam3. 1. Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea. 2. Department of Radiation Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea. 3. Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea. Electronic address: jhnam@amc.seoul.kr.
Abstract
OBJECTIVE: To develop a nomogram for predicting the probability of 5year survival after definitive concurrent chemoradiotherapy (CCRT) in locally advanced cervical cancer (LACC). METHODS: Between 1998 and 2008, 209 patients with LACC were treated with definitive CCRT. Multivariate analysis using Cox proportional hazards regression model was performed. A nomogram based on this Cox model was developed and internally validated by bootstrapping. Its performance was assessed by using the concordance index and a calibration curve. RESULTS: The median age was 55years (range, 26-78). Of the patients, 9, 16, 129, 3, 42 and 10 had FIGO stage IB2, IIA, IIB, IIIA, IIIB, and IVA disease, respectively. Histology revealed that 190, 13, 4, and 2 patients had squamous, adenocarcinoma, adenosquamous, and small cell cervical cancer, respectively. In 91 patients, PET/CT was performed before CCRT. The median follow-up period was 51months (range, 6-151) and there were 50 (23.9%) disease-related deaths. Multivariate regression analysis revealed that histology, tumor size, and paraaortic lymph node metastasis (defined by MRI), but not PET/CT before CCRT, were independent predictors of overall survival. A nomogram for predicting the 5year survival incorporating these three significant variables was constructed. The concordance index was 0.69. The predictive ability of the nomogram proved to be superior to that of the FIGO staging system (p<0.05). CONCLUSIONS: The nomogram was a better predictive model for overall survival than the FIGO staging system. If externally validated, it could be used to counsel patients with LACC who must choose additional treatment modalities after definitive CCRT.
OBJECTIVE: To develop a nomogram for predicting the probability of 5year survival after definitive concurrent chemoradiotherapy (CCRT) in locally advanced cervical cancer (LACC). METHODS: Between 1998 and 2008, 209 patients with LACC were treated with definitive CCRT. Multivariate analysis using Cox proportional hazards regression model was performed. A nomogram based on this Cox model was developed and internally validated by bootstrapping. Its performance was assessed by using the concordance index and a calibration curve. RESULTS: The median age was 55years (range, 26-78). Of the patients, 9, 16, 129, 3, 42 and 10 had FIGO stage IB2, IIA, IIB, IIIA, IIIB, and IVA disease, respectively. Histology revealed that 190, 13, 4, and 2 patients had squamous, adenocarcinoma, adenosquamous, and small cell cervical cancer, respectively. In 91 patients, PET/CT was performed before CCRT. The median follow-up period was 51months (range, 6-151) and there were 50 (23.9%) disease-related deaths. Multivariate regression analysis revealed that histology, tumor size, and paraaortic lymph node metastasis (defined by MRI), but not PET/CT before CCRT, were independent predictors of overall survival. A nomogram for predicting the 5year survival incorporating these three significant variables was constructed. The concordance index was 0.69. The predictive ability of the nomogram proved to be superior to that of the FIGO staging system (p<0.05). CONCLUSIONS: The nomogram was a better predictive model for overall survival than the FIGO staging system. If externally validated, it could be used to counsel patients with LACC who must choose additional treatment modalities after definitive CCRT.
Authors: Evis Sala; Maura Micco; Irene A Burger; Derya Yakar; Marisa A Kollmeier; Debra A Goldman; Mithat Gonen; Kay J Park; Nadeem R Abu-Rustum; Hedvig Hricak; Hebert Alberto Vargas Journal: Int J Gynecol Cancer Date: 2015-10 Impact factor: 3.437
Authors: Jason D Wright; Koji Matsuo; Yongmei Huang; Ana I Tergas; June Y Hou; Fady Khoury-Collado; Caryn M St Clair; Cande V Ananth; Alfred I Neugut; Dawn L Hershman Journal: Obstet Gynecol Date: 2019-07 Impact factor: 7.661
Authors: David Cibula; Lukáš Dostálek; Jiri Jarkovsky; Constantijne H Mom; Aldo Lopez; Henrik Falconer; Giovanni Scambia; Ali Ayhan; Sarah H Kim; David Isla Ortiz; Jaroslav Klat; Andreas Obermair; Giampaolo Di Martino; Rene Pareja; Ranjit Manchanda; Jan Kosťun; Ricardo Dos Reis; Mehmet Mutlu Meydanli; Diego Odetto; Rene Laky; Ignacio Zapardiel; Vit Weinberger; Klára Benešová; Martina Borčinová; Fernando Cardenas; Emelie Wallin; Luigi Pedone Anchora; Huseyin Akilli; Nadeem R Abu-Rustum; Salim Abraham Barquet-Muñoz; Veronika Javůrková; Daniela Fischerová; Luc R C W van Lonkhuijzen Journal: Gynecol Oncol Date: 2021-12-23 Impact factor: 5.304
Authors: David Lora; Agustín Gómez de la Cámara; Sara Pedraza Fernández; Rafael Enríquez de Salamanca; José Fermín Pérez Regadera Gómez Journal: J Gynecol Oncol Date: 2017-05-26 Impact factor: 4.401
Authors: Won Sup Yoon; Dae Sik Yang; Jung Ae Lee; Nam Kwon Lee; Young Je Park; Chul Yong Kim; Nak Woo Lee; Jin Hwa Hong; Jae Kwan Lee; Jae Yun Song Journal: Biomed Res Int Date: 2017-04-27 Impact factor: 3.411